Unum Therapeutics Inc (UMRX) Stock Price, Forecast & Analysis

USA • Nasdaq • NASDAQ:UMRX

2.35
+0.01 (+0.43%)
Last: Oct 5, 2020, 08:00 PM

UMRX Key Statistics, Chart & Performance

Key Statistics
Market Cap99.80M
Revenue(TTM)23.87M
Net Income(TTM)-23.11M
Shares42.47M
Float19.71M
52 Week High3.72
52 Week Low0.3
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.76
PEN/A
Fwd PEN/A
Earnings (Next)N/A
IPON/A
Sector
GICS SectorN/A
GICS IndustryN/A
GICS IndustryGroupN/A
GICS SubIndustryN/A
UMRX short term performance overview.The bars show the price performance of UMRX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 200 400

UMRX long term performance overview.The bars show the price performance of UMRX in the last 1, 2 and 3 years. 1 year 2 years 3 years 20 40 60

The current stock price of UMRX is 2.35 null. In the past month the price increased by 6.82%. In the past year, price increased by 67.86%.

Unum Therapeutics Inc / UMRX Daily stock chart

UMRX Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to UMRX. When comparing the yearly performance of all stocks, UMRX is one of the better performing stocks in the market, outperforming 79.87% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

UMRX Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to UMRX. UMRX may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

UMRX Financial Highlights

Over the last trailing twelve months UMRX reported a non-GAAP Earnings per Share(EPS) of -0.76. The EPS increased by 44.12% compared to the year before.


Industry RankSector Rank
PM (TTM) -96.84%
ROA -74.43%
ROE N/A
Debt/Equity 0.18
Chartmill High Growth Momentum
EPS Q2Q%29.41%
Sales Q2Q%-83.17%
EPS 1Y (TTM)44.12%
Revenue 1Y (TTM)98.25%

UMRX Forecast & Estimates


Analysts
Analysts86.6
Price TargetN/A
EPS Next Y75%
Revenue Next YearN/A

UMRX Ownership

Ownership
Inst Owners0%
Ins Owners34.59%
Short Float %N/A
Short RatioN/A

About UMRX

Company Profile

Unum Therapeutics Inc. is a biopharmaceutical company. It focused on the development and commercialization of novel immunotherapy products of immune system to cure cancer. The company's program consists of ACTR087 rituximab, ACTR707 RITUXIMAB, ACTR087 SEA-BCMA which are in clinical stage. Unum Therapeutics Inc. is based in Cambridge, United States.

Company Info

Unum Therapeutics Inc

200 CAMBRIDGE PARK DRIVE SUITE 3100

CAMBRIDGE MA 02140

CEO: Charles Wilson

Phone: 617-945-5576

Unum Therapeutics Inc / UMRX FAQ

What does Unum Therapeutics Inc do?

Unum Therapeutics Inc. is a biopharmaceutical company. It focused on the development and commercialization of novel immunotherapy products of immune system to cure cancer. The company's program consists of ACTR087 rituximab, ACTR707 RITUXIMAB, ACTR087 SEA-BCMA which are in clinical stage. Unum Therapeutics Inc. is based in Cambridge, United States.


Can you provide the latest stock price for Unum Therapeutics Inc?

The current stock price of UMRX is 2.35 null. The price increased by 0.43% in the last trading session.


Does Unum Therapeutics Inc pay dividends?

UMRX does not pay a dividend.


How is the ChartMill rating for Unum Therapeutics Inc?

UMRX has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


Would investing in Unum Therapeutics Inc be a good decision?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on UMRX.


What is Unum Therapeutics Inc worth?

Unum Therapeutics Inc (UMRX) has a market capitalization of 99.80M null. This makes UMRX a Micro Cap stock.